

MIV Global Medtech Fund

Sub-Fund of an investment company with variable capital SICAV



Monthly report February 2022

Marketing document for private and institutional investors

Facts Fund class I3

Net Asset Value per Fund share USD	3'035.41
Assets USD m (all Fund classes)	3'841
Investment level	100%
Liquidity	0%

Industry breakdown

In-vitro Diagnostics	11%
Disposable Medical Supplies	8%
Hospital Equipment	7%
Ophthalmology	6%
Surgical Instruments	6%
Dentistry	6%
Diabetes	5%
Endoscopy	5%
Transcatheter Heart Valve	5%
Other Medical Technology Sectors	41%


Holdings

Abbott Laboratories	9%	HOYA	3%
Intuitive Surgical	8%	Baxter	3%
Medtronic	8%	ResMed	3%
Stryker	6%	Sonova	3%
Edwards Lifesciences	6%	DexCom	3%
Becton Dickinson	5%	Steris	2%
Boston Scientific	5%	Straumann	2%
IDEXX Laboratories	4%	Thermo Fisher Scientific	2%
Align Technology	4%	Coloplast	2%
Alcon	3%	20 small holdings	20%

Currency breakdown

USD	77%	DKK	4%
CHF	8%	EUR	4%
JPY	7%		

Performance Fund class I3 USD



Important legal information

Past performance is not a reliable indicator of current or future performance. Performance data take no account of the commissions and costs charged when units are issued and redeemed. The return of the Fund may go down as well as up due to changes in rates of exchange between currencies.

Performance in USD

	February	2022	1 year	3 years	5 years	10 years	Inception
MIV Global Medtech Fund I3	0.8%	-11.7%	3.6%	38.6%	94.3%	n.a.	194.9%
Benchmark *	0.8%	-10.5%	4.4%	52.1%	116.8%	n.a.	233.4%
MSCI World Index	-2.5%	-7.7%	10.7%	49.9%	76.6%	n.a.	116.0%
			3.17-2.18	3.18-2.19	3.19-2.20	3.20-2.21	3.21-2.22
MIV Global Medtech Fund I3			19.4%	17.4%	4.4%	28.1%	3.6%
Benchmark *			22.6%	16.3%	9.9%	32.6%	4.4%
MSCI World Index			17.4%	0.4%	4.6%	29.3%	10.7%

* MSCI World Healthcare Equipment & Supplies

Company Headlines

Final quarter 2021 reporting by numerous companies and their outlooks for 2022 clearly showed that after pleasing business development in October and November, the highly infectious Omicron coronavirus strain detected for the first time towards the end of November had a negative impact on the number of elective surgeries and other medical treatments in December and January. Statements by the management of broadly diversified group **Medtronic** made in connection with the January close of the third quarter of fiscal year 2022, which ends in April, were very well received by investors. Following a further negative effect of Omicron on the number of operations in the first weeks of February, Medtronic has seen an improvement. Management expects procedure volumes to recover continuously in March and April, and to reach pre-pandemic levels by the end of April in most of the firm's markets. This catch-up effect due to the backlog in medical treatments should be comparable to that after the ebbing of previous waves of COVID-19.

After being favoured by investors in recent years and posting the strongest increases, shares in medical device suppliers with above-average growth suffered due to profit-taking in the first two months of this year. These include **Intuitive Surgical**, **Edwards Lifesciences**, **DexCom**, **Align Technology**, **Straumann** and **Sysmex**. By contrast, shares in companies with a more moderate growth profile such as **Stryker**, **Baxter**, **Sonova**, **Steris**, **CooperCompanies** and **Globus Medical** are trading only slightly lower, while those in **Medtronic**, **Becton Dickinson**, **Boston Scientific** and **Teleflex** even advanced in this volatile market environment. These firms tend to be classed by investors as "value" within the growth sector of medical devices and accordingly have a lower valuation than growth stocks. All of the above groups will benefit as the Omicron wave recedes in the coming weeks and months. By comparison, share prices of suppliers of tests, test kits and laboratory systems to detect coronavirus such as **Abbott Laboratories**, **Danaher** and **Thermo Fisher Scientific** and others active in the area of diagnostics and life sciences supply, including **IDEXX Laboratories** and **Sartorius**, suffered above-average losses after benefitting from the past two years of the pandemic.

The start of Russia's war against Ukraine on 24 February resulted in further sector rotations on the equity markets, some of which were counter to those in January. Many major medical device suppliers stated when asked that their business in these two countries was negligible or accounted for (far) less than 1% of group revenue. In the case of **Danaher**, it totals around 1% revenue, and at **Abbott Laboratories** and **Sysmex**, approximately 2%. In February, the MIV Global Medtech Fund was able to reduce the underperformance versus the global equity index MSCI World due to the sector rotation in January by roughly 3 percentage points.

Investments in medical devices

Investment Strategy

The MIV Global Medtech Fund invests globally in listed medical device companies. The investment process is based on a combined top-down / bottom-up approach. Against the background of the particular macroeconomic environment, the most interesting markets and companies are determined based on an intensive primary analysis. Alongside an attractive valuation, a strong market position, good growth potential, excellent products, sustainable profitability and high-quality management are the decisive parameters for investment. The consideration of sustainability criteria (ESG) is integrated in the research, analysis and investment process. Risks are managed by means of portfolio diversification. The portfolio of the MIV Global Medtech Fund is structured more defensively or cyclically in the best possible anticipation of economic trends, with a view to achieving a higher return than the benchmark and the general market indices.

Benefits

Owing to demographic trends and the desire for quality of life and mobility, the medical device industry is a long-term growth market. Emerging markets will have a positive impact on the medical device industry's future growth thanks to the state-backed expansion of their healthcare systems. Medical device suppliers' priority is the development of innovative, minimally invasive products. These are beneficial for patients and cost efficient for the healthcare system due to shorter convalescence periods. Most interesting from an investor's perspective are the industry's high growth rates, above-average profitability and oligopolistic market structures with their high entry barriers for new competitors. Even in a demanding environment, significant product innovations continue to offer attractive growth prospects.

Risks

The MIV Global Medtech Fund invests in equity securities and may therefore be subject to high fluctuations in value. For this reason, a medium-term to long-term investment horizon and corresponding risk tolerance and capacity are required for an investment into this Sub-Fund. As the MIV Global Medtech Fund pursues an active management style, the Sub-Fund's performance can deviate substantially from that of its reference index. The focus on equity securities of medical device companies exposes the Sub-Fund potentially to additional specific risks of this area of the healthcare industry. The Sub-Fund may, for the purpose of hedging and the efficient management of the portfolio, make use of derivatives, which can lead to additional risks (particularly counter party risk). All investments are subject to market fluctuations. Every Fund has specific risks, which can significantly increase under unusual market conditions.

Information

Website	www.mivglobalmedtech.ch
Legal structure	Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law
Fund class	I3 (USD) accumulation / ISIN: LU0969575645 / Swiss Valor Number: 22479883 / WKN: A1W7RK
Subscription/redemption	On every bank working day in Luxembourg until 3.45 p.m. at net asset value (no calculation of net asset values on bank/stock exchange holidays in Luxembourg and/or the US)
Management fee	0.8% p.a.
Total Expense Ratio (TER) as of 31.12.2021	0.94%
Launch of fund	11 March 2008
Launch of fund class I3	4 November 2013
Close of financial year	30 June
Benchmark	MSCI World Healthcare Equipment & Supplies
Reporting of the Portfolio manager	Monthly, semester and yearly report
Fund price monitoring	www.mivglobalmedtech.ch / www.swissfunddata.ch / www.fundinfo.com Bloomberg: VARI3US LX / Reuters: LU0969575645.LUF / Neue Zürcher Zeitung
Portfolio manager	MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, info@mivglobalmedtech.ch Contact: Jürg Nagel, Christoph Gubler, Giuseppe Di Benedetto, Phone +41 44 253 64 11
Management company	Vontobel Asset Management S.A., 18, rue Erasme, L-1468 Luxembourg
Representative in Switzerland	Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich
Custodian/Administrator	RBC Investor Services Bank S.A., 14, Porte de France, L-4360 Esch-sur-Alzette
Auditor	Ernst & Young S.A., 35E, Avenue John F. Kennedy, L-1855 Luxembourg
Minimum subscription	USD 500'000
Admissions to distribution	Switzerland, Germany, Austria, Liechtenstein, Luxembourg, France, Italy, Spain, United Kingdom, Netherlands, Finland, Norway, Sweden, Singapore (restricted scheme)
Distribution restrictions	USA / US persons

Sustainability profile - ESG

MIV Asset Management identifies, monitors and mitigates ESG risks that are, or could become, material to the performance of medical technology companies. The approach is based on the following factors:

- **Integration:** The consideration of sustainability criteria (ESG) is integrated into the research, analysis and investment process.
- **Exclusion:** The MIV Global Medtech Fund invests globally in listed medical technology companies. Investments in controversial industries are excluded (in particular pornography, alcohol, cluster munitions, gambling, landmines, mining, nuclear power, tobacco and armament dealing).
- **Best-in-class approach:** Diversified equity portfolio with below-average ESG risk. Investments with a Sustainability Controversy Rating of 5 (high) as well as a Sustainability ESG Risk Rating above 40 (severe) are excluded.
- **Dialogue:** MIV Asset Management maintains close and regular contact with the management of actual and potential investments, amongst other, with the goal of improving ESG practices and disclosure at these companies.
- **Ownership rights:** The active ownership approach includes exercising the MIV Global Medtech Fund's voting rights. These are delegated to the ISS proxy with Sustainability Policy. In case of controversial decisions, MIV Asset Management gets directly involved.

- ☑ The MIV Global Medtech Fund is classified as a financial product under **EU SFDR Article 8**
- ☑ MIV Asset Management is a signatory to the **UN Principles for Responsible Investment**
- ☑ The MIV Global Medtech Fund's investments support **UN Sustainable Development Goals 3, 8, 9 and 10**
- ☑ MIV Asset Management works together with the proxy **ISS** with **Sustainability Policy**
- ☑ The MIV Global Medtech Fund has an **above-average MSCI ESG score (6.2)** and **MSCI ESG rating (A)**
- ☑ The MIV Global Medtech Fund has an **above-average Sustainability ESG profile**

Investments in medical devices

Glossary

Benchmark	An index, which is used as a reference for the measurement of the performance of the Fund.
Inception	Launch date of the Fund and/or the Fund class.
Management fee	Portfolio manager's fee for the management and the distribution of the Fund.
NAV	Net Asset Value: total Fund assets divided by total number of Fund shares outstanding.
TER	Total Expense Ratio: sum of all fees and costs, which are charged to the Fund on a continuous basis.

Important legal information

MIV Global Medtech Fund is a Sub-Fund of Variopartner SICAV, an investment fund under Luxembourg law. This document is for information purposes only and nothing contained in this document should constitute a solicitation, or offer, or recommendation, to buy or sell any investment instruments, to effect any transactions, or to conclude any legal act of any kind whatsoever. This document has been produced by MIV Asset Management AG ("MIV AM"). It is explicitly not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association is not applicable. Although MIV AM believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this report. Any companies described in this document may or may not currently represent a position in the portfolio of the MIV Global Medtech Fund. Any projections, forecasts or estimates contained in this document are based on a variety of estimates and assumptions. There can be no assurance that the estimates or assumptions made will prove accurate, and actual results may differ materially.

Subscriptions of shares of the Sub-Fund should in any event be made solely on the basis of the current sales prospectus, the current Key Investor Information Document (KIID), the current articles of association and the most recent annual and semi-annual reports of Variopartner SICAV. For more details regarding the potential risks of an investment in Sub-Funds of Variopartner SICAV, please refer to the current sales prospectus. Interested parties may obtain the abovementioned documents free of charge from the Portfolio manager: MIV Asset Management AG, Feldeggstrasse 55, CH-8008 Zurich, the representative in Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, CH-8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, CH-8022 Zurich, the European facilities agent for Germany, Finland, France, the Netherlands and Norway: PwC Société coopérative – GFD, 2, rue Gerhard Mercator B.P. 1443, L-1014 Luxembourg, lu_pwc.gfd.facsvs@pwc.com, the financial and central administration agent in France: BNP Paribas Securities Services S.A., 3, Rue d'Antin, F-75002 Paris, the Austrian Facility: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna, the information agent in Liechtenstein: LLB Fund Services AG, Äulestrasse 80, FL-9490 Vaduz, the paying agents in Italy: RBC Investor Services Bank, Via Vittor Pisani, 26, I-20124 Milan, Allfunds Bank, S.A.U., Via Bocchetto, 6, I-20123 Milan, the facilities agent in the United Kingdom: Carne Financial Services (UK) LLP, 2nd Floor, 107 Cheapside, London EC2V 6DN, the paying agent in Sweden: Skandinaviska Enskilda Banken AB (publ), Investor Services/Paying Agent, AS-12, Råsta Strandväg 5, SE-169 79 Solna, from the offices of the Fund: Variopartner SICAV, 11–13, Boulevard de la Foire, L-1528 Luxembourg. They may also be downloaded from the website www.mivglobalmedtech.ch.

This Sub-Fund is registered with the Financial Conduct Authority (FCA) for public distribution in the United Kingdom.

This Sub-Fund is not available to retail investors in Singapore. It is accepted as restricted scheme by the Monetary Authority of Singapore (MAS) and may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore.

This Sub-Fund is not authorised by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong.

